AUSTRALIAN TELETRIAL PROGRAM REACHES SIGNIFICANT MILESTONES IN TRIALS AND PARTICIPANTS From origins in Townsville to being national program across multiple disease states and populations
Filmed in Brisbane & Townsville, Queensland and Darwin, Northern Territory | November 2024
Launched in 2022, the Australian Teletrial Program is an initiative designed to improve access to clinical trials for people living in regional and remote areas of Australia. It uses telemedicine and digital technologies to enable patients to participate in clinical trials without needing to travel long distances to major metropolitan centres, which can often be a barrier to participation for those in rural and isolated locations.
The program connects patients with researchers, medical professionals, and trial coordinators via video consultations and telehealth tools. This allows patients to receive treatment and follow-up care from their local healthcare providers, while still participating in high-quality clinical research.
Key Features of the Australian Teletrial Program:
- Remote Access to Trials: It facilitates the inclusion of patients from regional and remote areas who would otherwise have difficulty accessing clinical trials due to distance or travel constraints.
- Collaboration: The program involves partnerships between local healthcare providers, hospitals, research institutions, and trial sponsors. This collaborative model ensures that patients receive the best care and support throughout the trial process.
- Digital Health Technologies: Telehealth technologies, such as video conferencing, remote monitoring, and digital data collection, are used to manage patient care and ensure compliance with trial protocols.
- Widening Participation: It aims to diversify and increase the representation of regional and rural populations in clinical trials, which is important for trial results to include the broader population.
The Teletrial Program is part of a broader effort to improve the inclusivity and accessibility of medical research across Australia, ensuring that individuals, regardless of their location, have the opportunity to participate in cutting-edge clinical trials.
Recently Australian Health Journal met with Kaye Hewson, Director, Australian Teletrials Program, who spoke about the program’s recent achievements:
- Being a proven program outside of oncology, with clinical specialties such as respiratory, cardiac, diabetes, sexual health, mental health filling a gap in service and equity.
- In regional, rural and remote places, with adults and paediatrics involved in the program, a higher than national average participation rate of clinical trials by First Nations peoples in satellite locations.
- Savings of time, money and distance for those patients to satellite sites.
- Having over a thousand participants in teletrials across the six jurisdictions.
- Established collaborative and supportive mechanism and network around education and training.
Australian Health Journal also spoke with Melanie Poxton, Assistant Director of Nursing at the program’s Queensland Regional Clinical Trials Coordinating Centre (QRCCC) in Townsville University Hospital, North Queensland and Heather Parker, the Northern Territory Australian Teletrial Program Manager with NT Health.
Produced in collaboration with the Australian Teletrial Program.
-
New clinical research entity first to operate across both Australia and New Zealand
Over the past 30 years, 18,000 clinical trials that have been registered in Australia, with the sector contributing $1.4 billion to Australia’s economy annually. Trials are a critical aspect of evidence-based medicine, and are essential for testing how new treatments, tests and vaccines will work. In New Zealand they contribute $146 million to the New Zealand economy.
To capitalise on this unique position and growth, a coordinated multi-site clinical research operation was missing, until now.
-
Bionic eye trial shows improvements in functional vision for retinitis pigmentosa
Results of the first clinical trial of Australia’s ‘second generation’ bionic eye have demonstrated ‘substantial improvement’ in four participants’ functional vision, daily activities and quality of life over a period of more than two and a half years.
Led by the Centre for Eye Research Australia, Bionics Institute, University of Melbourne and Royal Victorian Eye and Ear Hospital, the trial findings add to interim results which showed that the second-generation bionic eye developed by Australian company Bionic Vision Technologies provided rapid improvements for four patients with blindness caused the genetic eye condition retinitis pigmentosa.
-
Entering The New Health Frontier
A new parliamentary report ‘The New Frontier: Delivering better health for all Australians’ is recommending significant reforms to the health care system to ensure Australians have better and faster access to the wave of new medicines and technologies.
The bipartisan report makes 31 recommendations to reform Australia’s system for the regulation and reimbursement with the hope that patients will receive faster access to the latest medicines and technologies.
